New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
07:08 EDTRXIIRXi Pharmaceuticals granted US Notice of Allowance for technology platform
RXi Pharmaceuticals received the Notice of Allowance from the USPTO on its novel, self-delivering RNAi platform. The patent broadly covers both the composition and methods of use of RXi's self-delivering platform technology. The patent, once issued, will be scheduled to expire in 2029.
News For RXII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 5, 2015
07:06 EDTRXIIRXi Pharmaceuticals granted Notice of Allowance from USPTO for use of technology
Subscribe for More Information
September 28, 2015
07:05 EDTRXIIRXi Pharmaceuticals granted patent in China for RXI-109
RXi Pharmaceuticals announced that it has been granted a patent from the State Intellectual Property Office of the People's Republic of China for the composition and methods of use for RXI-109 and other connective tissue growth factor targeting self-delivering RNAi compounds for the treatment of fibrotic disorders, including skin fibrosis. The patent is scheduled to expire in 2031. RXI-109 and other CTGF-targeting sd-rxRNA(R) compounds may be beneficial for the treatment of fibrotic diseases, including dermal scarring, a condition with a much higher prevalence in people with darker skin. Skin pigmentation is classified in VI categories known as the Fitzpatrick scale. In China, individuals tend to have skin types between III and V. The prevalence rates for hypertrophic scarring in individuals with higher-scoring Fitzpatrick phototypes can be up to 40-70% following surgery, making China a significant market for RXI-109 in the treatment of dermal scarring. According to Persistence Market Research, China is predicted to be one of the fastest growing markets for scar treatments in Asia.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use